Good glycemic control enhances maternal serum and milk prolactin concentrations and decreases the delay in the establishment of lactation that has been observed in mothers with type 1 diabetes (190,198)
As of December 2, 2024, there are 1,300 pending lawsuits in the consolidated lawsuits against Novo Nordisk and other GLP-1 manufacturers
There was inadequate data to assess response to combination therapy with both agents
Introduction Neurobehavioral and metabolic effects of GLP-1 RAs How GLP-1 RAs affect appetite Changes in cravings, mood, and behavior How GLP-1 drugs may reshape addiction pathways Clinical and public health implications Conclusions References Further reading The widely used obesity and diabetes GLP-1 drugs may do far more than reduce weight
Patients usually start losing weight within the first month, even at the starting dose of 0.25 mg
It is most often stacked with a GHRH analog for a larger GH pulse